Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Study finds LC damage and reduction in noradrenaline levels in brain are linked with MS

Study finds LC damage and reduction in noradrenaline levels in brain are linked with MS

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

First 7 stem cell lines grown at UMMS Human Stem Cell Bank ready for global distribution

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

New model of dementia care reduces emergency department visits, hospitalizations

New model of dementia care reduces emergency department visits, hospitalizations

Study finds high prevalence of HS-AGING in individuals older than 95

Study finds high prevalence of HS-AGING in individuals older than 95

Human-worm connection research provides insight into brain development, diseases

Human-worm connection research provides insight into brain development, diseases

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

People with memory problems may face high risk of stroke

People with memory problems may face high risk of stroke

Johns Hopkins funds 12 research groups to launch new BSi program on cognitive disorders

Johns Hopkins funds 12 research groups to launch new BSi program on cognitive disorders

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen third quarter total revenue increases 26% to $7,068,000

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Rapid detection of transiently folded single-molecule structures from 'intrinsically disordered proteins'

Rapid detection of transiently folded single-molecule structures from 'intrinsically disordered proteins'

Two new studies report GOT may improve health outcomes of stroke patients

Two new studies report GOT may improve health outcomes of stroke patients

Curaxis listed on Frankfurt Stock Exchange

Curaxis listed on Frankfurt Stock Exchange

Specific gene variation linked to late-onset Alzheimer's

Specific gene variation linked to late-onset Alzheimer's

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

Specific gene variation may play a role in late-onset Alzheimer's disease: New study

Scientists develop novel technique to detect disordered protein folding

Scientists develop novel technique to detect disordered protein folding

Positron anticipates expanded market opportunity for Attrius PET scanner

Positron anticipates expanded market opportunity for Attrius PET scanner

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.